Compugen Ltd
NASDAQ:CGEN

Watchlist Manager
Compugen Ltd Logo
Compugen Ltd
NASDAQ:CGEN
Watchlist
Price: 1.52 USD 7.8% Market Closed
Market Cap: 136.1m USD
Have any thoughts about
Compugen Ltd?
Write Note

Net Margin
Compugen Ltd

2.7%
Current
-308%
Average
0%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
2.7%
=
Net Income
1.6m
/
Revenue
59.9m

Net Margin Across Competitors

Country IL
Market Cap 136.1m USD
Net Margin
3%
Country US
Market Cap 1.3T USD
Net Margin
9%
Country US
Market Cap 196.2B USD
Net Margin
14%
Country US
Market Cap 170.9B USD
Net Margin
18%
Country KR
Market Cap 67.8T KRW
Net Margin
24%
Country CH
Market Cap 38.5B CHF
Net Margin
9%
Country US
Market Cap 38.6B USD
Net Margin
22%
Country US
Market Cap 36.5B USD
Net Margin
9%
Country US
Market Cap 26.7B USD
Net Margin
21%
Country US
Market Cap 23.2B USD
Net Margin
17%
Country US
Market Cap 23B USD
Net Margin
21%
No Stocks Found

Compugen Ltd
Glance View

Market Cap
136.1m USD
Industry
Life Sciences Tools & Services

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

CGEN Intrinsic Value
1.01 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
2.7%
=
Net Income
1.6m
/
Revenue
59.9m
What is the Net Margin of Compugen Ltd?

Based on Compugen Ltd's most recent financial statements, the company has Net Margin of 2.7%.